Modality
Vaccine
MOA
C5i
Target
CDK4/6
Pathway
Sphingolipid
SCLC
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Nov 2026
ApprovedCurrent
NCT06356494
1,725 pts·SCLC
2018-01→2026-11·Not yet recruiting
NCT04805544
2,036 pts·SCLC
2017-06→2025-03·Terminated
NCT05006210
2,588 pts·SCLC
2019-09→2026-06·Not yet recruiting
6,349 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2025-03-011.1y agoPh3 Readout· SCLC
2026-06-203mo awayPh3 Readout· SCLC
2026-11-198mo awayPh3 Readout· SCLC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Approved
Termina…
Approved
Not yet…
Approved
Not yet…
Catalysts
Ph3 Readout
2025-03-01 · 1.1y ago
SCLC
Ph3 Readout
2026-06-20 · 3mo away
SCLC
Ph3 Readout
2026-11-19 · 8mo away
SCLC
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06356494 | Approved | SCLC | Not yet recr... | 1725 | OS |
| NCT04805544 | Approved | SCLC | Terminated | 2036 | LiverFat |
| NCT05006210 | Approved | SCLC | Not yet recr... | 2588 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Rimanaritide | Agios | Phase 1 | CDK4/6 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| Lisosotorasib | Sobi | Phase 2/3 | CDK4/6 |